Your request has been received.
We will send you more information as it becomes available.
days to go: ASP+6% CMS reimbursement for proven non-opioids used in all outpatient surgical settings is coming January 1, 2025.
For adults, a maximum dose of 266 mg (20 mL) is recommended, based on:
For pediatric patients aged 6 to less than 17 years, dosing is weight based: 4 mg/kg (up to a maximum of 266 mg)
See how your peers are using EXPAREL for optimal pain coverage
Leading medical societies recommend opioid-minimizing pain management strategies to enhance recovery after plastic surgery
ASPS
Use of multimodal approaches should be considered over the use of single agents, particularly narcotics.1
ASPS, American Society of Plastic Surgeons.
In cosmetic procedures
4HR SHORTER mean length of stay in obesity class I mammaplasty patients vs bupivacaine HCI
(P=0.038)2*
39% REDUCED postoperative dose of hydromorphone in abdominoplasty as part of TAP block vs standard nerve block
(2.63 mg vs 4.31 mg; P=0.024)3†‡
In reconstructive procedures
24% REDUCED pain scores at discharge in mammaplasty vs presurgical paravertebral block
(3.2 vs 4.2; P <0.008)4§
47% REDUCED postsurgical opioid consumption in implant-based breast reconstruction vs bupivacaine HCI
(0.76 MED/h vs 1.43 MED/h; P=0.017)5‡¶
36% REDUCED length of stay in implant-based breast reconstruction vs bupivacaine HCI
(29.8 hours vs 46.7 hours; P=0.035)6¶
29% REDUCED mean total costs in abdominal wall & breast reconstruction procedures vs bupivacaine HCI
($28,021 vs $39,531; P=0.02)6#
*Retrospective review of reduction mammaplasty patients (N=113) treated with bupivacaine HCl (n=34) or EXPAREL (n=79).2
†Pilot study in which abdominoplasty patients (N=32) received either EXPAREL with TAP block (n=16) or a combination of pararectus injections and ilioinguinal/iliohypogastric nerve blocks (n=16).3
‡The clinical benefit of the decrease in opioid consumption was not demonstrated in pivotal trials.
§A retrospective review of patients (N=97) who underwent mastectomy with immediate tissue expander reconstruction using preoperative paravertebral block (n=53) compared with those treated with intraoperative EXPAREL infiltration (n=44).4
¶A prospective, randomized, single-blind trial comparing bupivacaine HCl (n=12) with EXPAREL (n=12) in patients undergoing implant-based breast reconstruction.5
#A retrospective claims analysis using the Vizient Clinical Data Base/Resource Manager abstract discharge database to identify abdominal wall and breast reconstruction procedures at participating hospitals.6
TAP, transversus abdominis plane.
ASP, average sales price; CMS, Centers for Medicare and Medicaid Services.
EXPAREL® (bupivacaine liposome injectable suspension) is indicated to produce postsurgical local analgesia via infiltration in patients aged 6 years and older and regional analgesia in adults via an interscalene brachial plexus nerve block, sciatic nerve block in the popliteal fossa, and an adductor canal block. Safety and efficacy have not been established in other nerve blocks.
Please refer to full Prescribing Information.
EXPAREL® (bupivacaine liposome injectable suspension) is indicated to produce postsurgical local analgesia via infiltration
This website uses cookies to give you a better browsing experience. By clicking the "Allow all cookies" button, you agree to our use of cookies. For additional information, see our Cookie Notice.